47 studies found for:    GS-7977 | Gilead [Lead]
Show Display Options
Rank Status Study
1 Completed GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Condition: Hepatitis C
Interventions: Drug: GS-7977;   Drug: RBV;   Drug: Placebo to match GS-7977;   Drug: Placebo to match RBV
2 Active, not recruiting Safety of Efficacy of GS-7977 and Ribavirin in Subjects With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
Conditions: Recurrent Chronic Hepatitis C Virus;   Post Liver Transplant
Interventions: Drug: GS-7977;   Drug: RBV
3 Active, not recruiting GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Conditions: Hepatitis C;   Cirrhosis;   Portal Hypertension;   With or Without Liver Decompensation
Interventions: Drug: GS-7977;   Drug: Ribavirin
4 Completed Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: PEG;   Drug: RBV
5 Active, not recruiting Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
6 Completed Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: Sofosbuvir;   Drug: EFV/FTC/TDF;   Drug: EFV;   Drug: ZDV/3TC;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: DRV;   Drug: RAL;   Drug: PEG;   Drug: RBV
7 Completed Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin
8 Completed Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
9 Completed
Has Results
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
10 Completed A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Conditions: Hepatitis C,;   Human Immunodeficiency Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
11 Active, not recruiting An Open-Label Study to Explore the Clinical Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Conditions: Hepatitis C;   Hepatocellular Carcinoma
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin
12 Recruiting Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: LDV/SOF FDC;   Drug: SOF;   Drug: RBV;   Drug: PEG;   Drug: GS-9669;   Drug: GS-5816
13 Completed Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Condition: Chronic Hepatitis C Infection
Interventions: Drug: PSI-7977;   Drug: Ribavirin;   Drug: Pegylated-Interferon;   Drug: GS-5885;   Drug: GS-9669;   Drug: Sofosbuvir/GS-5885 400/90 mg
14 Active, not recruiting Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
Condition: Chronic Hepatitis C Virus
Interventions: Drug: SOF/LDV;   Drug: RBV
15 Completed Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
Condition: Chronic Hepatitis C Virus
Interventions: Drug: LDV/SOF;   Drug: RBV
16 Approved for marketing Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
Condition: Post-transplant Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin;   Drug: Pegylated Interferon
17 Active, not recruiting Sofosbuvir+RBV for 16 or 24 Weeks and Sofosbuvir+PEG+RBV for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
18 Active, not recruiting An Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Subjects With Nosocomial Genotype 1 HCV Infection.
Condition: Hepatitis C
Intervention: Drug: SOF/LDV
19 Active, not recruiting Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection
Condition: Chronic HCV Infection
Interventions: Drug: SOF/LDV;   Drug: RBV;   Drug: GS-9669
20 Completed Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
Condition: Chronic Hepatitis C Virus
Interventions: Drug: LDV/SOF;   Drug: RBV

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years